Business Context and Reporting Period
Company: Neuralstem, Inc. (Note: Metadata referenced "Palisade Bio," but the filing text identifies the registrant as Neuralstem, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: Neuralstem is a pre-revenue biotechnology company focused on the development and commercialization of human neural stem cell therapies for neurodegenerative conditions. The company is currently in the pre-clinical stage, with its first Investigational New Drug (IND) application for Amyotrophic Lateral Sclerosis (ALS) filed in December 2008. As of the reporting date, the FDA has placed the trial on clinical hold pending protocol modifications.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Expenses | $5,636,208 | $5,263,986 |
| Operating Loss | $(5,636,208) | $(5,263,986) |
| Net Loss | $(2,283,769) | $(5,232,124) |
| Net Loss Per Share (Basic & Diluted) | $(0.07) | $(0.16) |
| Cash and Cash Equivalents (End of Period) | $3,218,321 | $6,966,587 |
| Net Cash Used in Operating Activities | $(2,528,277) | $(3,078,260) |
| Net Cash Provided by Financing Activities | $903,391 | $2,724,787 |
| Total Assets | $3,731,654 | $5,468,733 |
| Total Liabilities | $5,138,423 | $1,265,488 |
| Stockholders' Deficit | $(1,406,769) | $4,203,245 |
Material Changes vs. Prior Period
- Net Loss Improvement: The net loss for the six months ended June 30, 2009, decreased significantly to $2.28 million from $5.23 million in the prior year. This improvement was primarily driven by a non-cash gain of $3.34 million resulting from the change in fair value of warrant obligations.
- Accounting Reclassification: Effective January 1, 2009, the company adopted EITF 07-05, reclassifying approximately 8.5 million warrants from equity to liability status. This resulted in a long-term warrant liability of $6.6 million at the beginning of the year, which was marked down to $3.2 million by June 30, 2009.
- Equity Position: Due to the warrant reclassification and accumulated losses, the company moved from positive stockholders' equity of $4.2 million in 2008 to a deficit of $1.4 million in 2009.
- Operating Expenses: Operating expenses increased by approximately $372,000 year-over-year, largely due to increased non-cash stock-based compensation and legal fees related to ongoing litigation.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Capital Resources: The company reported a monthly cash burn rate of approximately $500,000. Management stated that as of June 30, 2009, cash reserves were sufficient to fund operations for at least six months, though this may require reductions in personnel or activities. Additional financing will be required to sustain operations and clinical trials.
- Listing Status Risk: On June 4, 2009, the NYSE Amex notified the company of non-compliance with continued listing requirements (specifically regarding stockholders' equity) due to the accounting reclassification. The company submitted a compliance plan on July 6, 2009. Failure to regain compliance could result in delisting and trading on the over-the-counter market.
- Regulatory Status: The company's IND for ALS treatment remains on clinical hold. The FDA requested modifications to the protocol in February 2009. The company is analyzing these comments to formulate a response.
- Legal Proceedings: The company is engaged in patent litigation with StemCells, Inc. regarding the validity and infringement of stem cell patents. Discovery has commenced, but no trial date has been set.
- Unusual Items: The financial results are heavily influenced by the non-cash gain/loss on warrant obligations, which does not reflect cash flow from operations.
Investor Verification Checklist
- Delisting Status: Verify the current status of the NYSE Amex compliance plan and whether the stock has been delisted or moved to OTC markets.
- IND Resolution: Confirm if the FDA clinical hold on the ALS trial has been lifted and if clinical trials have commenced.
- Cash Runway: Assess the current cash balance against the reported $500,000 monthly burn rate to determine the immediate need for capital raises.
- Warrant Liability: Monitor the fair value of the warrant liability, as fluctuations in stock price will directly impact reported net income/loss.
- Litigation Outcome: Review updates on the patent infringement lawsuit with StemCells, Inc., as an adverse ruling could threaten the company's core intellectual property.